Zoticon’s management team is comprised of pharmaceutical and biotech business development experts and experienced investment bankers located in the US, Europe, and Israel. Zoticon’s management team includes:
Asher has extensive biotech operating experience-- having started several biotech Companies including Intelligene and EvoRx. Both of these companies were formed around technologies which he invented. Intelligene was one of the pioneering biotech companies dealing with molecular evolution and attracted venture capital from the top international venture firms including Walden Investments, Advent and Rothschild Venture Capital. The technology was acquired by Genetico where it is actively being developed. EvoRx was founded together with Nobel Prize Winners: Arthur Kornberg and Roger Kornberg who is the head of Structural Biology at Stanford University. Jim Manuso, the current CEO of the successful, publicly traded company, Supergen, located in California was also involved in its formation. Asher has authored over 23 patents in the field of biotechnology and was a Managing Member in Molecular Intelligence, a biotechnology advisory company. Prior to founding Zoticon, he served for the past two years as a Managing Director at Paramount Biocapital, which is a top rated venture fund for in-licensing biotechnology transactions. His responsibility at Paramount included managing Paramount’s European office.
Robert was Managing Director at the Trout Group, a global investor relations and strategic advisory service dedicated solely to the life science industry. Prior to his work for Trout, he was a Senior Vice President at Gerard Klauer Mattison, a research and investment-banking firm. He last managed GKM’s European Corporate Finance divisions as well as international venture capital opportunities. He has completed over $2 billion in financing and advisory work and opened GKM's first international office.
